Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment

Article Details

Authors
Donata Galbiati MD, Stefano Cavalieri MD, Salvatore Alfieri MD, Carlo Resteghini MD, Cristiana Bergamini MD, Ester Orlandi MD, Francesca Platini MD, Laura Locati MD, Luca Giacomelli PhD, Lisa Licitra MD, Paolo Bossi MD

Article Type
Original Research

DOI
10.7573/dic.212611

Related Articles

Article Page

Abstract

Background: Unresectable or metastatic cutaneous squamous cell cancers (cSCCs) are rare but potentially life-threatening diseases. In this setting, systemic therapy has a palliative intent with limited benefit, but there is no established consensus regarding the proper management of this tumour. This retrospective study aimed to review outcomes in patients with non-curable cSCC treated with platinum-based chemotherapy and cetuximab.

Methods: We considered 12 consecutive patients treated between June 2010 and March 2016. All patients had received previous treatment for the local disease.

Results: The overall response rate was 50%, and the disease control rate was 67%. Median progression-free survival and overall survival were 6.6 (95% confidence interval [CI]: 1.9–8.4) and 14.6 (95% CI: 9.4–20.1) months, respectively. The median duration of response was 4.8 months (95% CI: 1.2–5.9). The most frequent toxicities were skin reactions (58%; grade 3: 25%) and anaemia (10%). No grade 4 toxicities were observed.

Conclusions: Cetuximab and platinum-based chemotherapy were shown to be feasible and active in cSCC, with an acceptable toxicity profile, even if with a limited duration of response.

Keywords: cetuximab, combination, cSCC, platinum-based chemotherapy.

Citation: Galbiati D, Cavalieri S, Alfieri S, Resteghini C, Bergamini C, Orlandi E, Platini F, Locati LD, Giacomelli L, Licitra LF, Bossi P. Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. Drugs in Context 2019; 8: 212611. DOI: 10.7573/dic.212611

Contributions: Data Collection: D.G., S.A., F.P. Data interpretation: P.B., C.B., L.L., L.G., L.F.L. Statistical analysis: S.C., C.R., E.O. Manuscript writing: P.B., D.G. Manuscript editing: all authors. Review and approval of the final draft: all authors. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: P.B.: Advisory board: Merck, Sanofi, Merck Sharp & Dohme, Sun Pharma, Angelini, AstraZeneca. Conference honoraria: Bristol-Myers Squibb, Kyowa Hakko Kirin, Angelini, Roche. L.G.: Consultancy: Eisai, LeoPharma, Grunenthal, Pierre-Fabre, Indena, Abbvie, CSL Behring, Santhera, Recordati. L.D.L.: Research funding: EISAI. Honoraria: EISAI; IPSEN; BMS; MSD; Merck Serono; Biogen; Eli Lilly. L.F.L.: Honoraria or consultation fees: (for public speaking/teaching in medical meetings and/or for expert opinion in advisory boards): Astrazeneca, Bayer, BMS, Eisai, MSD, Merck–Serono, Boehringer Ingelheim, Novartis, Roche, Debiopharm, Sobi, Incyte Biosciences Italy srl, Doxa Pharma srl, Amgen, Nanobiotics Sa, GSK. (For public speaking/teaching from research companies & commercial education providers): AccMed, Medical Science Fundation, G. Lorenzini, Associazione Sinapsi, Think 2 IT, Aiom Servizi, Prime Oncology, WMA Congress Education, Fasi, DueCi promotion Srl, MI&T, Net Congress & Education, PRMA Consulting, Kura Oncology, Health & Life srl, Ipsen Innovation, Immuno-Oncology Hub. Funding (to her institution) for clinical studies and research: Astrazeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis inc, Hoffmann-La roche ltd, IRX Therapeutics inc, Medpace inc, Merck–Serono, MSD, Novartis, Pfizer, Roche. Travel coverage for medical meetings: Merck–Serono, BMS, MSD, Debiopharm, Sobi, Bayer, Stilema, AccMed, Aiocc, Aiom. D.G., S.C., S.A., C.R., E.O., C.B., F.P. declare no conflict of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at https://www.drugsincontext.com/wp-content/uploads/2019/11/dic.212611-COI.pdf

Acknowledgements: Editorial assistance was provided by Laura Brogelli, PhD, and Aashni Shah (Polistudium SRL, Milan, Italy); this editorial assistance was paid for by Fondazione IRCCS Istituto Nazionale dei Tumori Milan, with funds assigned to P Bossi.

Funding declaration: There was no funding associated with the preparation of this article. No funding was received for this study.

Copyright: Copyright © 2019 Galbiati D, Cavalieri S, Alfieri S, Resteghini C, Bergamini C, Orlandi E, Platini F, Locati LD, Giacomelli L, Licitra LF, Bossi P. https://doi.org/10.7573/dic.212611. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2019 Galbiati D, Cavalieri S, Alfieri S, Resteghini C, Bergamini C, Orlandi E, Platini F, Locati LD, Giacomelli L, Licitra LF, Bossi P. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/activity-of-platinum-and-cetuximab-in-cutaneous-squamous-cell-cancer-not-amenable-to-curative-treatment/

Correspondence: Paolo Bossi, Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy. paolo.bossi@unibs.it

Provenance: submitted; externally peer reviewed.

Submitted: 18 July 2019; Peer review comments to author: 17 September 2019; Revised manuscript received: 15 November 2019; Accepted: 20 November 2019; Publication date: 19 December 2019.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF